XKRX
293480
Market cap111mUSD
Oct 08, Last price
8,470.00KRW
1D
-0.12%
1Q
-1.63%
IPO
-69.65%
Name
Hana Pharm Co Ltd
Chart & performance
P/E
17.10
P/S
0.63
EPS
495.29
Div yield, %
3.07%
Shrs. gr., 5y
0.54%
Rev. gr., 5y
6.20%
Revenues
239.50b
+6.29%
Net income
8.78b
-58.69%
CFO
9.18b
-63.73%
Dividend
Dec 29, 2025260 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hana Pharm Co., Ltd. is a pharmaceutical enterprise that manufactures and supplies a diverse range of medicinal goods to both domestic South Korean and international markets. Its comprehensive product line covers various therapeutic categories, such as anesthetics, potent narcotic pain relievers, anti-nausea agents, muscle relaxants, and treatments targeting the cardiovascular, endocrine, gastrointestinal, respiratory, and central nervous systems. Furthermore, the company offers antibiotics, dermatological preparations, urological medications, osteoporosis therapies, and medications for pain, fever, and inflammation. The firm was established in 1958 and has its corporate headquarters located in Seoul, South Korea.
Key people
Dong Hun Cho
Vice President, Director
Dong Yil Yang
Vice President
Seung Su Han
Managing Director
Yong Yeon Hwang
Managing Director
Yeong Seon Lee
Managing Director
Geun Hong Min
Managing Director
Managing Director
So Yun Chi
Assistant Managing Director
Gye Nam Cho
Assistant Managing Director
Yeong Su Kim
Internal Auditor
Jun Won Lee
Assistant Managing Director · since 2024
Jeong Wu Lee
Assistant Managing Director
Yil Gi Lee
Assistant Managing Director
Internal Auditor · since 2024
Hyeon Chae Shin
Internal Auditor
Cheol Hui Suhk
Assistant Managing Director
Ye Rim Cho
Director
Tae Hong Choi
Chief Executive Officer, Director · since 2024
Hong Ju Yoon
Assistant Managing Director
Non-Executive Independent Director
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||